Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity-Reference-Cited by-同舟云学术

Engineering of a Potent, Long-Acting NPY2R Agonist for Combination with a GLP-1R Agonist as a Multi-Hormonal Treatment for Obesity

Published:2020-08-26 Issue:17 Volume:63 Page:9660-9671
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lear Sam¹,Pflimlin Elsa¹,Zhou Zhihong¹,Huang David¹,Weng Sharon²,Nguyen-Tran Van¹,Joseph Sean B.¹,Roller Shane¹,Peterson Scott²,Li Jing¹,Tremblay Matthew¹^ORCID,Schultz Peter G.¹^ORCID,Shen Weijun¹^ORCID

Affiliation:

1. The Scripps Research Institute, d/b/a Calibr, a division of Scripps Research, 11119 North Torrey Pines Road, Suite 100, La Jolla, California 92037, United States

2. Intarcia Therapeutics, Inc., Research Triangle Park, 6 Davis Drive, Durham, North Carolina 27709, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00740

Reference55 articles.

1. Chronic disease burden associated with overweight and obesity in Ireland: the effects of a small BMI reduction at population level

2. Obesity: Overview of an Epidemic

3. Health Effects of Overweight and Obesity in 195 Countries over 25 Years

4. Addressing the Unmet Medical Need for Safe and Effective Weight Loss Therapies

5. The future role of gut hormones in the treatment of obesity

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evolution of peptide YY analogs for the management of type 2 diabetes and obesity;Bioorganic Chemistry;2023-11

2. Engineering a potent and long-acting GLP-1/Y2 receptor dual agonist as a multi-agonist therapy for diabetes and obesity;Peptides;2023-11

3. Screening of the Key Genes and Signaling Pathways for Schizophrenia Using Bioinformatics and Next Generation Sequencing Data Analysis;2023-10-29

4. Discovery of a potent and long-acting Xenopus GLP-1-based GLP-1/glucagon/Y2 receptor triple agonist;European Journal of Medicinal Chemistry;2023-02

5. Design of Xenopus GLP-1-Based Long-Acting Dual GLP-1/Y₂ Receptor Agonists;Journal of Medicinal Chemistry;2022-10-10